Mutual of America Capital Management LLC Purchases 10,726 Shares of Supernus Pharmaceuticals, Inc. $SUPN

Mutual of America Capital Management LLC raised its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 5.3% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 212,691 shares of the specialty pharmaceutical company’s stock after purchasing an additional 10,726 shares during the quarter. Mutual of America Capital Management LLC owned approximately 0.38% of Supernus Pharmaceuticals worth $6,704,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in SUPN. Yousif Capital Management LLC raised its stake in Supernus Pharmaceuticals by 1.5% in the second quarter. Yousif Capital Management LLC now owns 21,032 shares of the specialty pharmaceutical company’s stock valued at $663,000 after purchasing an additional 305 shares in the last quarter. Meritage Portfolio Management grew its holdings in shares of Supernus Pharmaceuticals by 2.7% during the second quarter. Meritage Portfolio Management now owns 60,398 shares of the specialty pharmaceutical company’s stock worth $1,904,000 after purchasing an additional 1,595 shares during the last quarter. CWM LLC grew its holdings in shares of Supernus Pharmaceuticals by 92.4% during the second quarter. CWM LLC now owns 3,080 shares of the specialty pharmaceutical company’s stock worth $97,000 after purchasing an additional 1,479 shares during the last quarter. Vanguard Personalized Indexing Management LLC bought a new stake in shares of Supernus Pharmaceuticals during the second quarter worth about $205,000. Finally, Maryland State Retirement & Pension System boosted its holdings in Supernus Pharmaceuticals by 2.2% in the second quarter. Maryland State Retirement & Pension System now owns 16,455 shares of the specialty pharmaceutical company’s stock valued at $519,000 after acquiring an additional 361 shares during the last quarter.

Wall Street Analysts Forecast Growth

SUPN has been the topic of several recent analyst reports. Zacks Research raised Supernus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, September 17th. Piper Sandler upgraded Supernus Pharmaceuticals from a “neutral” rating to an “overweight” rating and upped their price objective for the company from $40.00 to $65.00 in a research note on Thursday, October 9th. Weiss Ratings restated a “hold (c)” rating on shares of Supernus Pharmaceuticals in a research note on Wednesday, October 8th. Wall Street Zen downgraded Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, October 3rd. Finally, Cantor Fitzgerald upped their price objective on Supernus Pharmaceuticals from $46.00 to $63.00 and gave the company an “overweight” rating in a research note on Tuesday, September 30th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $64.00.

Insider Activity

In other news, CFO Timothy C. Dec sold 11,780 shares of Supernus Pharmaceuticals stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $44.49, for a total transaction of $524,092.20. Following the completion of the sale, the chief financial officer owned 1,246 shares in the company, valued at approximately $55,434.54. This trade represents a 90.43% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Frank Mottola sold 5,000 shares of Supernus Pharmaceuticals stock in a transaction dated Friday, September 12th. The shares were sold at an average price of $45.87, for a total value of $229,350.00. Following the sale, the senior vice president owned 15,496 shares of the company’s stock, valued at approximately $710,801.52. This trade represents a 24.40% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 362,741 shares of company stock worth $16,390,592. 8.80% of the stock is currently owned by insiders.

Supernus Pharmaceuticals Trading Up 2.8%

Shares of SUPN opened at $51.59 on Tuesday. The company has a market cap of $2.89 billion, a PE ratio of 44.86 and a beta of 0.78. The stock has a 50-day moving average price of $46.12 and a 200-day moving average price of $37.45. Supernus Pharmaceuticals, Inc. has a 12-month low of $29.16 and a 12-month high of $52.15.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.